NewsRx

Search our medical news database

Aeolus Pharmaceuticals, Inc.

Pharmaceutical company records loss of $0.12 per share, reports on ALS drug

Published in Lab Business Week, June 12th, 2005

Aeolus Pharmaceuticals, Inc., (AOLS.OB) announced the financial results for its second quarter of fiscal 2005, the 3-month period ended March 31, 2005, and provided an update on its drug for amyotrophic lateral sclerosis (ALS).

Aeolus reported a net loss of $1,659,000, or $0.12 per share, for the 3 months ended March 31, 2005, and a net loss of $3,616,000, or $0.26 per share, for the 6 months ended March 31, 2005. This compares with a net loss of $2,308,000 for the 3 months ended March 31, 2004, and a net loss attributable to common stockholders of $4,786,000 for the 6 months ended March 31, 2004.

On March 29, 2005, Aeolus announced interim results...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook